Skip to main content
. 2017 Oct 5;8(58):98200–98214. doi: 10.18632/oncotarget.21516

Figure 3. IL-6 diminishes the immunostimulating effects of Lenalidomide.

Figure 3

MNC were incubated with peptide-loaded DC in the presence of CD8+CD28– T-cells and were coincubated with lenalidomide (Len., 10 μM) and IL-6 (3 ng/ml), with lenalidomide alone or without as the negative control (Contr.). After 12 d, the expanded antigen-specific T-cells were activated with peptide-loaded T2 cells for 48 hrs. The frequency of antigen-specific T-cells from 6 HDs was detected by IFN-y-ELISpot assay (A). An exemplary ELISpot analysis is shown. Supernatants of the 48 hrs-incubation settings were harvested to determine Granzyme B release of the antigen-specific T-cells of 5 HDs (B). Cells after 12 d incubation were stained for CD3 and CD8 and for CD45RA (C) or CD28 (D) (HD, n = 8) and then were analyzed by flow cytometry. In all of the experiments, the incubations with the controls were set at 100%. An exemplary CD45RA-flow cytometry analysis is demonstrated. The numbers in the quadrants show the frequency of CD45RA+ cells as a fraction of gated CD3+CD8+ lymphocytes.